NAMS MENOPAUSE CERTIFICATION
EXAM (MSCP) 2026 – COMPLETE
PRACTICE QUESTION BANK: 400
QUESTIONS WITH VERIFIED ANSWERS
& RATIONALES | ALREADY GRADED A+
| GUARANTEED PASS!! [MOST
RECENT!!]
Question 1: Continued vasomotor symptoms in a 52-year-old postmenopausal
woman with hysterectomy receiving 0.3 mg oral conjugated equine estrogens can
best be managed by:
• Answer: Increasing the daily estrogen dose.
• Rationale: The patient is on the lowest FDA-approved dose of CEE (0.3 mg).
With persistent symptoms despite adequate treatment duration (typically 4-8
weeks), dose escalation is appropriate. Since she had a hysterectomy, no
progestogen is needed .
Question 2: Which agent is best to treat moderate hot flashes in a 55-year-old
woman with history of breast cancer?
• Answer: Paroxetine.
• Rationale: Systemic estrogen is contraindicated in breast cancer survivors.
Paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for vasomotor
symptoms (VMS) and is a preferred non-hormonal option .
Question 3: Which strategy helps reduce VTE risk with HRT?
• Answer: Use transdermal estrogen instead.
• Rationale: Transdermal estrogen avoids first-pass hepatic metabolism,
resulting in a lower impact on coagulation factors and a lower VTE risk
compared to oral estrogen .
Question 4: What is the risk of hormone therapy in women with history of VTE?
• Answer: B) Increased risk, especially with oral estrogen.
, • Rationale: Women with a history of VTE have increased risk with hormone
therapy, especially with oral estrogen. Transdermal estrogen is preferred if HT
is deemed necessary, but in many cases HT is contraindicated .
Question 5: 46-year-old female with pain with intercourse (hysterectomy, ovaries
remain), no other menopausal symptoms. Best treatment:
• Answer: Intravaginal estrogen only.
• Rationale: Symptoms are localized (no VMS). Ovaries remain so estrogen
production continues. Intravaginal estrogen targets genitourinary syndrome of
menopause (GSM) locally. No progestogen is needed as there is no uterus .
Question 6: A 55-year-old woman has been on HT for 10 years and asks about
continuing. What is the most appropriate recommendation?
• Answer: Discuss risks/benefits and consider tapering.
• Rationale: Long-term HT use (over 5 years) requires ongoing risk-benefit
assessment. Shared decision-making about continuation or tapering is
essential .
Question 7: Best treatment option for 54-year-old postmenopausal woman with
vaginal dryness, itching, and dyspareunia (intact uterus):
• Answer: Intravaginal estrogen cream.
• Rationale: Local therapy is first-line for GSM. It has minimal systemic
absorption and no endometrial protection is needed with low-dose vaginal
estrogen .
Question 8: What is the "climacteric phase"?
• Answer: The period of endocrinologic, somatic, and transitory psychologic
changes around the time of menopause.
• Rationale: It encompasses the transition from the reproductive stage to the
non-reproductive stage .
Question 9: What is the effect of hormone therapy on colorectal cancer risk?
• Answer: B) Decreases risk.
• Rationale: The WHI found a significant reduction in colorectal cancer risk with
estrogen-progestin therapy (RR 0.56). This is considered a potential benefit
but not a primary indication for hormone therapy .
Question 10: What is the recommended duration of use for hormone therapy?
• Answer: D) Individualized based on risk-benefit assessment.
, • Rationale: The NAMS recommends that hormone therapy be used at the
lowest effective dose for the shortest duration consistent with treatment
goals. Duration should be individualized based on the woman's risk profile
and symptom burden .
Question 11: What is the effect of hormone therapy on bone mineral density in
postmenopausal women?
• Answer: C) Increases BMD.
• Rationale: Hormone therapy increases bone mineral density by 2-4% per year
and reduces the risk of hip and vertebral fractures. This is a well-established
benefit and the basis for FDA approval for osteoporosis prevention .
Question 12: What is the effect of hormone therapy on migraine headaches in
perimenopausal women?
• Answer: Usually improves migraines.
• Rationale: Hormone therapy often improves migraines in perimenopausal
women by stabilizing estrogen levels, which prevents the estrogen withdrawal
that can trigger migraines. Transdermal estrogen is preferred for migraineurs .
Question 13: What is the recommended management for a woman with newly
diagnosed endometrial cancer who has menopausal symptoms?
• Answer: C) Non-hormonal treatments.
• Rationale: Systemic hormone therapy is contraindicated in women with a
history of endometrial cancer. Vaginal estrogen is generally not
recommended, though some experts may consider it in select cases. Non-
hormonal treatments should be used .
Question 14: What is the effect of menopause on asthma?
• Answer: B) Worsens asthma.
• Rationale: Some women experience worsening of asthma during the
menopausal transition, possibly related to hormonal changes. Hormone
therapy has variable effects on asthma and should be used with caution .
Question 15: What is the recommended treatment for a woman with premature
ovarian insufficiency (POI) who desires symptom relief?
• Answer: B) Hormone therapy until the average age of menopause.
• Rationale: Women with POI should receive hormone therapy until the
average age of natural menopause (approximately 51 years) to protect against
cardiovascular disease and osteoporosis. This is distinct from standard
menopause HT .
, Question 16: What is the recommended management for a woman with a history of
venous thromboembolism (VTE) who has severe vasomotor symptoms?
• Answer: C) Non-hormonal treatments.
• Rationale: Hormone therapy is contraindicated in women with a history of
VTE. Non-hormonal options such as paroxetine, gabapentin, or fezolinetant
should be used for vasomotor symptom management .
Question 17: What is the effect of hormone therapy on the risk of ovarian cancer?
• Answer: D) Variable effect.
• Rationale: The effect of hormone therapy on ovarian cancer risk is uncertain.
Some studies suggest a small increased risk with long-term use, while others
show no significant association. The absolute risk is low .
Question 18: What is the role of pelvic floor physical therapy in managing
genitourinary syndrome of menopause (GSM)?
• Answer: B) Improves urinary and sexual function.
• Rationale: Pelvic floor physical therapy can improve urinary symptoms, sexual
function, and pelvic floor strength in women with GSM. It should be
considered as an adjunct to vaginal estrogen and other treatments .
Question 19: What is the recommended initial dose of vaginal estrogen ring
(Estring)?
• Answer: B) 5 mcg daily.
• Rationale: The vaginal estradiol ring (Estring) delivers 5 mcg of estradiol daily
over 90 days for treatment of vaginal atrophy .
Question 20: What is the role of ospemifene in menopause management?
• Answer: Treats dyspareunia due to GSM.
• Rationale: Ospemifene is a selective estrogen receptor modulator (SERM)
approved for the treatment of moderate to severe dyspareunia (vaginal pain
with intercourse) due to GSM .
Question 21: Which of the following is a contraindication to hormone therapy?
• Answer: Undiagnosed vaginal bleeding.
• Rationale: Undiagnosed vaginal bleeding is a contraindication to hormone
therapy. The source must be investigated before starting or continuing
therapy .
Question 22: What is the effect of hormone therapy on the risk of cardiovascular
disease when initiated in women aged 50-59?
EXAM (MSCP) 2026 – COMPLETE
PRACTICE QUESTION BANK: 400
QUESTIONS WITH VERIFIED ANSWERS
& RATIONALES | ALREADY GRADED A+
| GUARANTEED PASS!! [MOST
RECENT!!]
Question 1: Continued vasomotor symptoms in a 52-year-old postmenopausal
woman with hysterectomy receiving 0.3 mg oral conjugated equine estrogens can
best be managed by:
• Answer: Increasing the daily estrogen dose.
• Rationale: The patient is on the lowest FDA-approved dose of CEE (0.3 mg).
With persistent symptoms despite adequate treatment duration (typically 4-8
weeks), dose escalation is appropriate. Since she had a hysterectomy, no
progestogen is needed .
Question 2: Which agent is best to treat moderate hot flashes in a 55-year-old
woman with history of breast cancer?
• Answer: Paroxetine.
• Rationale: Systemic estrogen is contraindicated in breast cancer survivors.
Paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for vasomotor
symptoms (VMS) and is a preferred non-hormonal option .
Question 3: Which strategy helps reduce VTE risk with HRT?
• Answer: Use transdermal estrogen instead.
• Rationale: Transdermal estrogen avoids first-pass hepatic metabolism,
resulting in a lower impact on coagulation factors and a lower VTE risk
compared to oral estrogen .
Question 4: What is the risk of hormone therapy in women with history of VTE?
• Answer: B) Increased risk, especially with oral estrogen.
, • Rationale: Women with a history of VTE have increased risk with hormone
therapy, especially with oral estrogen. Transdermal estrogen is preferred if HT
is deemed necessary, but in many cases HT is contraindicated .
Question 5: 46-year-old female with pain with intercourse (hysterectomy, ovaries
remain), no other menopausal symptoms. Best treatment:
• Answer: Intravaginal estrogen only.
• Rationale: Symptoms are localized (no VMS). Ovaries remain so estrogen
production continues. Intravaginal estrogen targets genitourinary syndrome of
menopause (GSM) locally. No progestogen is needed as there is no uterus .
Question 6: A 55-year-old woman has been on HT for 10 years and asks about
continuing. What is the most appropriate recommendation?
• Answer: Discuss risks/benefits and consider tapering.
• Rationale: Long-term HT use (over 5 years) requires ongoing risk-benefit
assessment. Shared decision-making about continuation or tapering is
essential .
Question 7: Best treatment option for 54-year-old postmenopausal woman with
vaginal dryness, itching, and dyspareunia (intact uterus):
• Answer: Intravaginal estrogen cream.
• Rationale: Local therapy is first-line for GSM. It has minimal systemic
absorption and no endometrial protection is needed with low-dose vaginal
estrogen .
Question 8: What is the "climacteric phase"?
• Answer: The period of endocrinologic, somatic, and transitory psychologic
changes around the time of menopause.
• Rationale: It encompasses the transition from the reproductive stage to the
non-reproductive stage .
Question 9: What is the effect of hormone therapy on colorectal cancer risk?
• Answer: B) Decreases risk.
• Rationale: The WHI found a significant reduction in colorectal cancer risk with
estrogen-progestin therapy (RR 0.56). This is considered a potential benefit
but not a primary indication for hormone therapy .
Question 10: What is the recommended duration of use for hormone therapy?
• Answer: D) Individualized based on risk-benefit assessment.
, • Rationale: The NAMS recommends that hormone therapy be used at the
lowest effective dose for the shortest duration consistent with treatment
goals. Duration should be individualized based on the woman's risk profile
and symptom burden .
Question 11: What is the effect of hormone therapy on bone mineral density in
postmenopausal women?
• Answer: C) Increases BMD.
• Rationale: Hormone therapy increases bone mineral density by 2-4% per year
and reduces the risk of hip and vertebral fractures. This is a well-established
benefit and the basis for FDA approval for osteoporosis prevention .
Question 12: What is the effect of hormone therapy on migraine headaches in
perimenopausal women?
• Answer: Usually improves migraines.
• Rationale: Hormone therapy often improves migraines in perimenopausal
women by stabilizing estrogen levels, which prevents the estrogen withdrawal
that can trigger migraines. Transdermal estrogen is preferred for migraineurs .
Question 13: What is the recommended management for a woman with newly
diagnosed endometrial cancer who has menopausal symptoms?
• Answer: C) Non-hormonal treatments.
• Rationale: Systemic hormone therapy is contraindicated in women with a
history of endometrial cancer. Vaginal estrogen is generally not
recommended, though some experts may consider it in select cases. Non-
hormonal treatments should be used .
Question 14: What is the effect of menopause on asthma?
• Answer: B) Worsens asthma.
• Rationale: Some women experience worsening of asthma during the
menopausal transition, possibly related to hormonal changes. Hormone
therapy has variable effects on asthma and should be used with caution .
Question 15: What is the recommended treatment for a woman with premature
ovarian insufficiency (POI) who desires symptom relief?
• Answer: B) Hormone therapy until the average age of menopause.
• Rationale: Women with POI should receive hormone therapy until the
average age of natural menopause (approximately 51 years) to protect against
cardiovascular disease and osteoporosis. This is distinct from standard
menopause HT .
, Question 16: What is the recommended management for a woman with a history of
venous thromboembolism (VTE) who has severe vasomotor symptoms?
• Answer: C) Non-hormonal treatments.
• Rationale: Hormone therapy is contraindicated in women with a history of
VTE. Non-hormonal options such as paroxetine, gabapentin, or fezolinetant
should be used for vasomotor symptom management .
Question 17: What is the effect of hormone therapy on the risk of ovarian cancer?
• Answer: D) Variable effect.
• Rationale: The effect of hormone therapy on ovarian cancer risk is uncertain.
Some studies suggest a small increased risk with long-term use, while others
show no significant association. The absolute risk is low .
Question 18: What is the role of pelvic floor physical therapy in managing
genitourinary syndrome of menopause (GSM)?
• Answer: B) Improves urinary and sexual function.
• Rationale: Pelvic floor physical therapy can improve urinary symptoms, sexual
function, and pelvic floor strength in women with GSM. It should be
considered as an adjunct to vaginal estrogen and other treatments .
Question 19: What is the recommended initial dose of vaginal estrogen ring
(Estring)?
• Answer: B) 5 mcg daily.
• Rationale: The vaginal estradiol ring (Estring) delivers 5 mcg of estradiol daily
over 90 days for treatment of vaginal atrophy .
Question 20: What is the role of ospemifene in menopause management?
• Answer: Treats dyspareunia due to GSM.
• Rationale: Ospemifene is a selective estrogen receptor modulator (SERM)
approved for the treatment of moderate to severe dyspareunia (vaginal pain
with intercourse) due to GSM .
Question 21: Which of the following is a contraindication to hormone therapy?
• Answer: Undiagnosed vaginal bleeding.
• Rationale: Undiagnosed vaginal bleeding is a contraindication to hormone
therapy. The source must be investigated before starting or continuing
therapy .
Question 22: What is the effect of hormone therapy on the risk of cardiovascular
disease when initiated in women aged 50-59?
